Digital Oral Presentation Session 7 – Management of perianal and luminal disease

  • 17:20 - 18:20 Digital Oral Presentation Session 7 – Management of perianal and luminal disease
    Chairs:
    Willem Bemelman, Amsterdam, The Netherlands
    Tom Oresland, Lorenskog, Norway
      17:20-17:26 DOP055: Results of the Fifth Scientific Workshop of ECCO (II): Clinical aspects of perianal fistulising Crohn's Disease - The unmet needs


    Gecse, K.
    1, Sebastian, S.2, de Hertogh, G.3, Yassin, N.4, Kotze, P.5, Reinisch, W.6, Spinelli, A.7, Koutroubakis, I.8, Katsanos, K.9, Hart, A.10, van den Brink, G.11, Rogler, G.12, Bemelman, W.13

    1
    Semmelweis University, First Department of Medicine, Budapest, Hungary, 2Hull; East Yorkshire NHS Trust, Inflammatory Bowel Disease Unit, Hull, United Kingdom, 3University of Leuven, Department of Pathology, Leuven, Belgium, 4St Mark's Hospital and Academic Institute, Department of Colorectal Surgery, London, United Kingdom, 5Catholic University of Paraná, Colorectal Surgery Unit, Curitiba, Brazil, 6Medical University of Vienna, Department of Gastroenterology, Vienna, Austria, 7Humanities University, Colorectal Surgery Unit, Humanitas Research Hospital, Milano, Italy, 8University Hospital Heraklion, Department of Gastroenterology, Heraklion, Greece, 9School of Health Sciences, Division of Gastroenterology, Department of Medicine, Ioannia, Greece, 10St. Mark’s Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom, 11Academic Medical Centre, University of Amsterdam, Department of Gastroenterology, Amsterdam, Netherlands, 12University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 13Academic Medical Centre, University of Amsterdam, Department of Surgery, Amsterdam, Netherlands
      17:26-17:32 DOP056: Pathophysiology of perianal Fistulising Disease

    Siegmund, B.1, Feakins, R.M.2, Barmias, G.3, Coelho Ludvig, J.4, Vieira Teixeira, F.5, Rogler, G.6, Scharl, M.7


    1Charite Berlin, Berlin, Germany, 2Royal London Hospital, London, United Kingdom, 3Ethnikon and Kapodistriakon University of Athens, Athens, Greece, 4Santa Isabel Hospital Blumenau, Santa Catarina, Brazil, 5Gastrosaude Clinic, Sao Paulo, Brazil, 6University Hospital Zürich, Zürich, Switzerland, 7University Hospital Zürich, Division of Gastroenterology and Hepatology, Zürich, Switzerland
      17:32-17:38 DOP057: Perianal pediatric Crohn's Disease is associated with a distinct phenotype and greater inflammatory burden

    Assa, A.
    1, Amitai, M.2, Greer, M.-L.3, Castro, D.3, Cytter Kuint, R.4, Martínez-León, M.5, Herman-Sucharska, I.6, Coppenrath, E.7, Anupindi, S.8, Towbin, A.9, Moote, D.10, Konen, O.11, Pratt, L.-T.12, Grifitths, A.3, Turner, D.4


    1Schneider Children's medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Sheba Medical Center, Department of Radiology, Ramat Gan, Israel, 3Hospital for Sick Children, Toronto, Canada, 4Shaare Zedek Medical Center, Jerusalem, Israel, 5Hospital Regional Universitario Carlos Haya, Malaga, Spain, 6Jagiellonian University in Cracow, Cracow, Poland, 7University of Munich, Munich, Germany, 8The Children's Hospital of Philadelphia, Philadelphia, United States, 9Cincinnati Children's Hospital, Cincinnati, United States, 10Connecticut Children’s Medical Center, Hartford, United States, 11Schneider Children's medical Center, Petach Tikva, Israel, 12Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
      17:38-17:44 DOP058: Does biologic therapy increase the risk for fistula-associated mucinous adenocarcinoma in long standing perianal Crohn’s Disease?

    Laureti, S.
    , Coscia, M., Gentilini, L., Gionchetti, P., Renzi, N., Rizzello, F., Tanzanu, M., Poggioli, G.


    University of Bologna, Department of Gastroenterology and Surgical Sciences, Bologna, Italy
      17:44-17:50 DOP059: New human gut xenograft mouse model for intestinal fistulas

    Bruckner, R.S.1,2
    , Marsiano, N.3, Nissim-Eliraz, E.3, Nir, E.3, Lang, S.1,2, Spalinger, M.1,2, Rogler, G.1,4, Yagel, S.5, SysmedIBD EU research consortium, Scharl *, M.1,4, Shpigel *, N.Y.3, * Authors contributed equa


    1University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Zurich, Zurich, Switzerland, 3Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel, 4University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland, 5Hadassah University Hospital, Obstetrics and Gynecology, Jerusalem, Israel
      17:50-17:56 DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn’s Disease and Ulcerative Colitis in the United States


    Siegel, C.1
    , Yang, F.2, Eslava, S.2, Cai, J.2


    1Dartmouth-Hitchcock Medical Center, Lebanon, United States, 2Celgene Corporation, Summit, United States
      17:56-18:02 DOP061: Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with Innovator Infliximab (INX) in patients with active Crohn’s Disease: Early efficacy and safety results

    Kim, Y.H.
    1, Ye, B.D.2, Pesegova, M.3, Alexeeva, O.4, Osipenko, M.5, Lahat, A.6, Dorofeyev, A.7, Salamon, A.8, Fishman, S.9, Levchenko, O.10, Cheon, J.H.11, Scribano, M.L.12, Mateescu, R.-B.13, Lee, K.M.14, Eun, C.S.15, Lee, S.J.16, Lee, S.Y.16


    1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Krasnoyarsk Regional clinical hospital, Krasnoyarsk, Russian Federation, 4Nizhny Novgorod Regional Clinical Hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation, 5Novosibirsk State Medical University, Novosibirsk, Russian Federation, 6Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel, 7Medical Center LLC Ukrainian German Antiulcer Gastroenterology Center BIK Kyiv, Kyiv, Ukraine, 8Tolna Megyei Balassa János Kórház, Szekszárd, Hungary, 9Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 10Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine, 11Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 12Azienda Ospedaliera San Camillo Forlanini, Roma, Italy, 13Gastroenterology Dept. at Colentina Clinical Hospital AND "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, 14St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea, 15Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea, 16CELLTRION, Inc., Incheon, South Korea
       18:02-18:08 DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Explorative IBD subgroup-analyses in Crohn's Disease and Ulcerative Colitis from the NOR-Switch trial

    Jørgensen, K.K.
    1, Olsen, I.C.2, Goll, G.L.2, Lorentzen, M.3, Bolstad, N.4, Berset, I.P.5, Haavardsholm, E.A.2,6, Lundin, K.E.6,7,8, Mørk, C.9, Kvien, T.K.2,6, Jahnsen, J.1,6, and The Nor-Switch Study Group


    1Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 3Oslo University Hospital, Rikshospitalet, Department of Dermatology, Oslo, Norway, 4Oslo University Hospital, Radiumhospitalet, Department of Medical Biochemistry, Oslo, Norway, 5Ålesund Hospital, Department of Gastroenterology, Ålesund, Norway, 6University of Oslo, Faculty of Medicine, Oslo, Norway, 7Oslo University Hospital, Rikshospitalet, Department of Gastroenterology, Oslo, Norway, 8Centre for Immune Regulation, Department of Immunology, Oslo, Norway, 9Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway
       18:08-18:14 DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in Inflammatory Bowel Disease patients

    Taxonera, C.1
    , Ponferrada, A.2, Bermejo, F.3, Gisbert, J.P.4, Riestra, S.5, Saro, C.6, Cabriada, J.L.7, Barreiro-de Acosta, M.8, Barrio, J.9, Flores, E.10, Ferrer, I.11, Hernandez, A.12, Van Domselaar, M.13, Olivares, D.1, Alba, C.1, Fernández-Salazar, L.14, Merino, O.15, Botella, B.16, Ceballos, D.17, Moral, I.18, Peñate, M.19, Algaba, A.3, on behalf of the SEGURTB study group from GETE


    1Hospital Clinico San Carlos, IdISSC, Madrid, Spain, 2Hospital Infanta Leonor, Madrid, Spain, 3Hospital de Fuenlabrada, Madrid, Spain, 4Hospital Universitario de La Princesa, CIBERehd, Madrid, Spain, 5Hospital Central De Asturias, Oviedo, Spain, 6Hospital De Cabueñes, Gijón, Spain, 7Hospital San Eloy, Baracaldo, Spain, 8Hospital de Santiago De Compostela, Santiago de Compostela, Spain, 9Hospital Río Hortega, Valladolid, Spain, 10Hospital Universitario Reina Sofía, CIBERehd, Córdoba, Spain, 11Hospital de Manises, Manises, Spain, 12Hospital Universitario De Canarias, Santa Cruz De Tenerife, Spain, 13Hospital de Torrejón, Madrid, Spain, 14Hospital Clinico de Valladolid, Valladolid, Spain, 15Hospital De Cruces, Bilbao, Spain, 16Hospital Universitario Infanta Cristina, Madrid, Spain, 17Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 18Hospital Príncipe De Asturias, Madrid, Spain, 19Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain